The goal of this proposal is to continue a Clinical Center of TrialNet at the University of California at San Francisco (UCSF), with the ultimate long-term objectives to better understand the natural history and pathogenesis of type 1 diabetes mellitus (T1D), and to develop therapies to preserve endogenous insulin secretion in those with new onset T1D, and to prevent (T1D). UCSF is uniquely positioned to serve as a Clinical Center for TrialNet, given a well renowned clinical diabetes program;a large population base for subject recruitment;and a strong established track record with clinical research and autoimmune interventions for T1D. In addition, the center has Clinical and Translational Science Institute (CTSI) funding, with both a Pediatric and General Clinical Research Center (PCRC, GCRC), and investigators with extensive experience in both basic science and clinical research. This proposal will extend UCSF's past role as a Clinical Center in TrialNet. Specifically, the study goals are:
Specific Aim 1) To continue in our role as a Clinical Center for TrialNet, completing existing studies and developing and implementing new protocols in the network. To that end, we will continue our present plans to maximize recruitment for studies by increasing awareness amongst health care professionals and affected subjects and families. We will continue to foster relationships with a large affiliated network throughout Northern California and the Pacific Islands. We will recruit, enroll, and retain subjects within these studies according to the highest GCP standards.
Specific Aim 2 : We propose a novel phase II study to determine the safety and efficacy of Imatinib in preserving endogenous beta cell function in subjects with new onset T1D. This tyrosine kinase inhibitor has proven highly effective in therapy for specific cancers, and has more recently been shown to modulate autoimmunity in pre-clinical and clinical settings. In the NOD mouse, Imatinib induces remission in animals with new onset DM, and the drug can be withdrawn with the animals sustaining a durable remission, suggesting that it is tolerizing. We propose a multi-center, double-arm, blinded, placebo-controlled, 2:1 randomized, phase II clinical trial for individuals with recent onset T1D.
Type 1 diabetes mellitus (T1D) is a chronic autoimmune disease in which insulin producing beta cells are completely destroyed by autoreactive T cells, resulting in a dependence on exogenous insulin for life. Current management of T1D is not optimal, with risk for recurrent hypoglycemia and long term complications relating to chronic hyperglycemia. The goals of the proposed studies are to prevent T1D, or to preserve endogenous insulin secretion in those with recent onset disease, so as to prevent the morbidity and mortality associated with this condition.
|Nathan, Brandon M; Boulware, David; Geyer, Susan et al. (2017) Dysglycemia and Index60 as Prediagnostic End Points for Type 1 Diabetes Prevention Trials. Diabetes Care 40:1494-1499|
|Bosi, Emanuele; Boulware, David C; Becker, Dorothy J et al. (2017) Impact of Age and Antibody Type on Progression From Single to Multiple Autoantibodies in Type 1 Diabetes Relatives. J Clin Endocrinol Metab 102:2881-2886|
|Sosenko, Jay M; Yu, Liping; Skyler, Jay S et al. (2017) The Use of Electrochemiluminescence Assays to Predict Autoantibody and Glycemic Progression Toward Type 1 Diabetes in Individuals with Single Autoantibodies. Diabetes Technol Ther 19:183-187|
|Hao, Wei; Wookwyk, Alyssa; Beam, Craig et al. (2017) Assessment of ? Cell Mass and Function by AIRmax and Intravenous Glucose in High-Risk Subjects for Type 1 Diabetes. J Clin Endocrinol Metab 102:4428-4434|
|Steck, Andrea K; Xu, Ping; Geyer, Susan et al. (2017) Can Non-HLA Single Nucleotide Polymorphisms Help Stratify Risk in TrialNet Relatives at Risk for Type 1 Diabetes? J Clin Endocrinol Metab 102:2873-2880|
|Writing Committee for the Type 1 Diabetes TrialNet Oral Insulin Study Group; Krischer, Jeffrey P; Schatz, Desmond A et al. (2017) Effect of Oral Insulin on Prevention of Diabetes in Relatives of Patients With Type 1 Diabetes: A Randomized Clinical Trial. JAMA 318:1891-1902|
|Yip, Linda; Fuhlbrigge, Rebecca; Atkinson, Mark A et al. (2017) Impact of blood collection and processing on peripheral blood gene expression profiling in type 1 diabetes. BMC Genomics 18:636|
|Ferrara, Christine T; Geyer, Susan M; Evans-Molina, Carmella et al. (2017) The Role of Age and Excess Body Mass Index in Progression to Type 1 Diabetes in At-Risk Adults. J Clin Endocrinol Metab 102:4596-4603|
|Ferrara, Christine Therese; Geyer, Susan Michelle; Liu, Yuk-Fun et al. (2017) Excess BMI in Childhood: A Modifiable Risk Factor for Type 1 Diabetes Development? Diabetes Care 40:698-701|
|Sosenko, Jay M (2016) Staging the progression to type 1 diabetes with prediagnostic markers. Curr Opin Endocrinol Diabetes Obes 23:297-305|
Showing the most recent 10 out of 65 publications